Drug intelligence / Profile preview

RJ019

Development stage: Preclinical
Lead developer: Risen Medical Technology
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

RJ019 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Risen Shanghai Medical Technology (Risen Pharma) for the treatment of metabolic diseases. As an siRNA molecule, it is designed to utilize the RNA interference (RNAi) pathway to silence the expression of a specific gene involved in metabolic regulation. While the exact molecular target of RJ019 remains undisclosed by the developer, it is part of a broader pipeline of oligonucleotide-based therapies at Risen Pharma aimed at addressing cardiometabolic and cardiovascular conditions.

Beyond the preview

Go deeper on RJ019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJ019.

Explore the full profile